Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Rare diseases focused Mereo BioPharma said data from a trial of its treatment for osteogenesis imperfecta would be presented at a key industry conference in Orlando.
The study results had been selected for a 'late-breaking oral presentation' on 20 September at the American Society for Bone and Mineral Research conference.
At 1:19pm: (LON:MPH) Mereo Biopharma Group Ltd share price was +2p at 68p